Biomea Fusion, Inc.
BMEANasdaqCIK 1840439HealthcareFiscal year ends Dec 31
Reports and events: 109 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2024-03-0721:02 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-062154 |
| 2024-01-1021:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-005929 |
| 2023-10-3020:30 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-056381 |
| 2023-10-3020:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-056335 |
| 2023-07-3120:12 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-035946 |
| 2023-07-3120:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-035939 |
| 2023-07-2520:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-193428 |
| 2023-06-1520:05 ET | 8-K | 5.07 Shareholder vote results | 0001193125-23-167884 |
| 2023-05-0221:01 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-132621 |
| 2023-05-0220:21 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-016700 |
| 2023-05-0220:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-016684 |
| 2023-04-2820:05 ET | DEF 14A | Proxy statementPeriod 2023-06-14 | 0001193125-23-126879 |
| 2023-04-0320:40 ET | SC 13D/A | Ownership report, active investor, amended | 0000929638-23-001060 |
| 2023-04-0320:06 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-089530 |
| 2023-03-2821:06 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-082314 |
| 2023-03-2820:30 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-010312 |
| 2023-03-2820:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-010286 |
| 2023-01-1221:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-007186 |
| 2022-12-1621:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-307318 |
| 2022-12-1321:14 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-303796 |
| 2022-11-2518:59 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-22-292554 |
| 2022-11-0721:13 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0000950170-22-022607 |
| 2022-11-0721:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-022598 |
| 2022-11-0120:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-274908 |
| 2022-10-1820:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-264447 |
| 2022-09-2322:48 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-249373 |
| 2022-09-2221:34 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-248476 |
| 2022-09-0920:02 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-22-241932 |
| 2022-08-2912:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-231908 |
| 2022-08-0120:21 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0000950170-22-013678 |
| 2022-08-0120:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-013673 |
| 2022-06-2320:01 ET | 8-K | 5.07 Shareholder vote results | 0001193125-22-180040 |
| 2022-06-0620:16 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-168339 |
| 2022-05-1611:44 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0000950170-22-009947 |
| 2022-05-1611:38 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-009945 |
| 2022-04-2920:06 ET | DEF 14A | Proxy statementPeriod 2022-06-22 | 0001193125-22-133569 |
| 2022-04-2211:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-22-114094 |
| 2022-04-0820:17 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-100349 |
| 2022-02-2821:16 ET | 10-K | Annual reportPeriod 2021-12-31 | 0001564590-22-007624 |
| 2022-02-2821:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-22-007616 |
| 2022-01-1214:25 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-22-007375 |
| 2021-11-1521:03 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-21-329816 |
| 2021-11-0320:11 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0001564590-21-053957 |
| 2021-11-0320:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-053938 |
| 2021-09-1720:13 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-21-276144 |
| 2021-08-1120:26 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0001564590-21-043461 |
| 2021-08-1120:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-043443 |
| 2021-07-1913:02 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-21-218136 |
| 2021-07-1220:53 ET | 8-K/A | 5.02 Departure or appointment of officers or directors | 0001193125-21-213137 |
| 2021-07-0920:40 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-21-211906 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.